Search
Chlorobutanol
go.drugbank.com/drugs/DB11386ApprovedVet approvedWithdrawnChlorobutanol, or chlorbutol, is an alcohol-based preservative with no surfactant activity . It also elicits sedative-hypnotic and weak local anesthetic actions in addition to antibacterial and antifungal properties. Similar in nature to...
Gemtuzumab ozogamicin
go.drugbank.com/drugs/DB00056ApprovedInvestigationalGemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzuma...
Copper histidinate
go.drugbank.com/drugs/DB32041ApprovedMenkes disease is a rare, X-linked recessive disorder caused by pathogenic variants in the ATP7A gene, which encodes a copper transport protein essential for absorbing dietary copper and transporting it across the blood-brain barrier. In...
Bufexamac
go.drugbank.com/drugs/DB13346ApprovedWithdrawnBufexamac is a non-steroidal anti-inflammatory drug (NSAID) under the market name Droxaryl, Malipuran, Paraderm and Parfenac. It is typically administered topically for the treatment of subacute and chronic eczema of the skin, including ...
Synonyms: 2-(p-Butoxyphenyl)-acetohydroxamic acid, p-Butoxyphenylacetohydroxamic acidZidovudine
go.drugbank.com/drugs/DB00495ApprovedInvestigationalA dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid c...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesQL1706
go.drugbank.com/drugs/DB17562InvestigationalQL1706 is an investigational bifunctional antibody that combines the activity of both PD-1 and CTLA-4 antibodies.
Navafenterol
go.drugbank.com/drugs/DB19195InvestigationalNavafenterol is under investigation in clinical trial NCT02971293 (Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871).
Bremelanotide
go.drugbank.com/drugs/DB11653Approved[L9635] Bremelanotide was first described in the literature in 2003 when it was known by the investigational code PT-141.
Categories: Melanocortin Receptor Agonists, Receptor, Melanocortin, Type 3, agonistsProtamine sulfate
go.drugbank.com/drugs/DB09141ApprovedInvestigationalSince it's earliest discovery in salmon rine sperm heads in the late 1800's to its formal introduction via US FDA approval in 1939, protamine sulfate has occupied an important therapeutic niche as perhaps … The agent elicits this heparin reversal predominantly via the formation of an inactive complex between the anionic nature of heparin and its own cationic state [A174778, A174781, L5371].
Aprocitentan
go.drugbank.com/drugs/DB15059ApprovedInvestigationalEndothelin receptor antagonism provides a novel therapeutic pathway for the management of patients with resistant hypertension.
Categories: Endothelin Receptor Antagonists, P-glycoprotein substrates